AVD-104 yielded sustained vision improvements in patients with geographic atrophy, with no statistical difference reported in the rate of change in GA area vs. monthly avacincaptad pegol, according to a press release.
The phase 2a SIGLEC trial randomly assigned 300 patients with GA to treatment with an intravitreal dose of either 2 mg AVD-104 (Aviceda Therapeutics), a poly sialic acid-coated nanoparticle, every other month (100 patients), 1 mg AVD-104 monthly (100 patients) or 2 mg avacincaptad pegol (100 patients) for 24 months. Patients had an average age of 79 years and an average baseline